Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-1473 long-term safety study in ulcerative colitis
2018-002135-19Phase 3Terminated
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of izencitinib in autoimmune colitis, sponsored by Theravance Biopharma, Inc. Primary endpoint: Long-term safety and tolerability. Started Feb 2019; status: terminated.
02
Drugs
izencitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-002135-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002135-19.